Acurx Pharmaceuticals Receives Mixed Analyst Ratings Amidst Financial Losses
Acurx Pharmaceuticals (NASDAQ: ACXP) is attracting attention from Wall Street analysts, with recent ratings offering a mixed outlook for the clinical-stage biopharmaceutical company. While Alliance Global Partners and H.C. Wainwright have issued ‘Buy’ ratings, TipRanks – DeepSeek maintains a ‘Hold’ rating on the stock.
Analyst Perspectives
James Molloy, a Managing Director and Biotechnology & Specialty Pharmaceuticals Equity Research Analyst at Alliance Global Partners, reiterated a ‘Buy’ rating on Acurx Pharmaceuticals, setting a price target of $10.00. Molloy’s coverage includes healthcare stocks such as Pelthos Therapeutics, Tonix Pharma, and Soligenix. However, his historical stock recommendations have yielded an average return of -25.0% with a 19.00% success rate.
Matthew Keller from H.C. Wainwright also issued a ‘Buy’ rating for Acurx today, indicating a positive sentiment towards the company’s prospects.
Financial Performance
Acurx Pharmaceuticals recently reported a quarterly GAAP net loss of $7.96 billion for the quarter ending December 31. This represents a significant increase compared to the GAAP net loss of $2.78 million reported during the same period last year.
Recent Clinical Trial Updates and FDA Interactions
Recent inquiries from James Molloy of Alliance Global Partners focused on the timeline for a recurrent Clostridioides difficile infection (CDI) trial. Specifically, he questioned the full enrollment duration for the Phase II pilot study and the potential for interim data to expedite the start of a Phase III trial.
David Luci, President and CEO of Acurx, indicated that full enrollment for the 20-patient pilot study is anticipated 12-15 months after its Q4 2026 start. While the company aims to evaluate all 20 patients, a preliminary assessment of the first 10 patients after eight weeks is planned, with the possibility of accelerating the Phase III trial based on the scientific advisory board’s recommendation.
Regarding the FDA’s recently announced ‘one trial requirement’ for registration, Executive Chairman Robert DeLuccia expressed optimism, citing insights from former FDA antimicrobials division head Mark Goldberger, who believes the change will be formalized with new guidance. Mr. Luci further supported this view, referencing a New England Journal of Medicine paper co-authored by Marty Makary, head of the FDA, as evidence of the impending change.
About Alliance Global Partners and James Molloy
James Molloy is a Managing Director and Biotechnology and Specialty Pharmaceuticals Equity Research Analyst at A.G.P./Alliance Global Partners. He specializes in coverage of companies within the biotechnology and pharmaceutical sectors, with a particular focus on immuno-oncology, central nervous system disorders, cardiovascular diseases, and anti-infective disorders. Mr. Molloy has nearly two decades of experience as a Senior Analyst covering mid-capitalization and emerging biotechnology and pharmaceutical companies.